Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN016 MIFTS: 64	Adenocarcinoma Categories: Cancer diseases, Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma ¹¹ ²⁸ ⁵³ ⁵ ⁴³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Adenocarcinoma and Carcinoid Combined of Unspecified Site ³³

Adenocarcinoid Tumour of Unspecified Site ³³

Adenoacanthoma of Unspecified Site ³³

Adenocarcinoid of Unspecified Site ³³

Adenocarcinoma Nos ³³

Adenocarcinomas ¹⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of ill-defined or unspecified primary sites

Adenocarcinoma of unspecified site

External Ids:

Disease Ontology ¹¹ DOID:299

MeSH ⁴³ D000230

NCIt ⁴⁹ C2852

SNOMED-CT ⁶⁸ 35917007

EFO ¹⁶ EFO_0000228

ICD11 ³³ 1979211198

UMLS ⁷¹ C0001418

Sources

Summaries for Adenocarcinoma

Disease Ontology: ¹¹ A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary: Adenocarcinoma, also known as adenocarcinoma and carcinoid combined of unspecified site, is related to pancreatic adenocarcinoma and appendix adenocarcinoma. An important gene associated with Adenocarcinoma is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Gene expression (Transcription) and Disease. The drugs Iron isomaltoside 1000 and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and pancreas, and related phenotypes are Decreased viability and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia: ⁷⁵ Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Sources

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2906)

#	Related Disease	Score	Top Affiliating Genes
1	pancreatic adenocarcinoma	33.4	TP53 TGFBR2 SMAD4 PIK3CA KRAS ERBB2
2	appendix adenocarcinoma	33.4	TP53 SMAD4 KRAS
3	small intestine adenocarcinoma	33.3	TP53 SMAD4 KRAS
4	endometrial adenocarcinoma	33.3	TP53 KRAS EGFR CDKN2A AKT1
5	mucinous adenocarcinoma	33.3	TP53 SMAD4 PIK3CA MUC1 KRAS ERBB2
6	colon adenocarcinoma	33.2	TP53 SMAD4 PIK3CA KRAS EGFR CDH1
7	barrett esophagus	33.2	TP53 SMAD4 ERBB2 CDKN2A APC
8	papillary adenocarcinoma	33.2	TP53 MUC1 KRAS ERBB2
9	cervical adenocarcinoma	33.1	TP53 KRAS CDKN2A BRAF
10	suppression of tumorigenicity 12	33.1	TP53 SMAD4 PIK3CA ERBB2 EGFR CDKN2A
11	ovary adenocarcinoma	33.1	TP53 PIK3CA MUC1 KRAS ERBB2 EGFR
12	gastric adenocarcinoma	33.1	TP53 SMAD4 PIK3CA KRAS H19 ERBB2
13	rectum adenocarcinoma	33.0	TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
14	colorectal adenocarcinoma	33.0	TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
15	bronchiolo-alveolar adenocarcinoma	33.0	TP53 KRAS EGFR CDH1
16	signet ring cell adenocarcinoma	33.0	TP53 MUC1 KRAS ERBB2 CDH1
17	pancreatic ductal adenocarcinoma	33.0	TP53 SMAD4 KRAS H19
18	tubular adenocarcinoma	32.9	MUC1 ERBB2 CDH1
19	adenocarcinoma in situ	32.9	TP53 KRAS EGFR CDKN2A
20	breast adenocarcinoma	32.9	TP53 PIK3CA MUC1 KRAS H19 ERBB2
21	barrett's adenocarcinoma	32.9	TP53 ERBB2 CDKN2A
22	ampulla of vater adenocarcinoma	32.9	SMAD4 MUC1 KRAS
23	gallbladder adenocarcinoma	32.8	TP53 MUC1 ERBB2
24	endometrial mucinous adenocarcinoma	32.8	KRAS CDKN2A
25	scirrhous adenocarcinoma	32.8	ERBB2 CDH1
26	esophagus adenocarcinoma	32.8	TP53 HNF1A-AS1 ERBB2 EGFR CDKN2A CDH1
27	gastroesophageal junction adenocarcinoma	32.8	TP53 ERBB2 EGFR
28	gastroesophageal adenocarcinoma	32.8	TP53 PIK3CA KRAS ERBB2 EGFR AKT1
29	lung cancer susceptibility 3	32.8	TP53 TGFBR2 SMAD4 RB1 PIK3CA MUC1
30	renal cell carcinoma, papillary, 1	32.7	TP53 PIK3CA KRAS ERBB2 EGFR CDKN2A
31	papillary serous adenocarcinoma	32.7	TP53 KRAS ERBB2
32	endocervical adenocarcinoma	32.7	TP53 SMAD4 PIK3CA ERBB2 CDKN2A
33	adenosquamous carcinoma	32.7	MUC1 KRAS EGFR
34	endometrial serous adenocarcinoma	32.7	TP53 PIK3CA KRAS ERBB2 ATM
35	sebaceous adenocarcinoma	32.7	TP53 ERBB2 CDKN2A
36	esophageal cancer	32.7	TP53 TGFBR2 SMAD4 RB1 PIK3CA KRAS
37	thyroid gland follicular carcinoma	32.6	TP53 PIK3CA CDH1 BRAF AKT1
38	serous cystadenocarcinoma	32.6	TP53 PIK3CA KRAS ERBB2 CDKN2A CDH1
39	diffuse gastric cancer	32.6	TP53 TGFBR2 SMAD4 PIK3CA KRAS ERBB2
40	apocrine adenocarcinoma	32.6	TP53 PIK3CA ERBB2 EGFR
41	vaginal cancer	32.6	TP53 EGFR CDKN2A
42	diffuse gastric and lobular breast cancer syndrome	32.6	TP53 SMAD4 PIK3CA KRAS ERBB2 EPCAM
43	inflammatory breast carcinoma	32.5	ERBB2 EGFR CDH1
44	bile duct adenocarcinoma	32.5	TP53 KRAS EGFR CDH1 AKT1
45	adenoid cystic carcinoma	32.5	TP53 PIK3CA MUC1 KRAS ERBB2 EGFR
46	chromophobe renal cell carcinoma	32.4	TP53 PIK3CA ERBB2 EGFR CDH1 AKT1
47	colorectal adenoma	32.4	TP53 SMAD4 KRAS EGFR CDH1 APC
48	renal cell carcinoma, nonpapillary	32.3	TP53 TGFBR2 PIK3CA MUC1 KRAS H19
49	pulmonary adenocarcinoma in situ	32.3	TP53 KRAS EGFR
50	pancreatic foamy gland adenocarcinoma	32.3	TP53 MUC1

Graphical network of the top 20 diseases related to Adenocarcinoma:

Sources

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 38)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	11.16	BRAF EGFR KRAS MUC1 PIK3CA
2	Decreased viability	GR00055-A-2	11.16	BRAF EGFR KRAS MUC1 PIK3CA
3	Decreased viability	GR00055-A-3	11.16	KRAS
4	Decreased viability	GR00106-A-0	11.16	KRAS
5	Decreased viability	GR00107-A-1	11.16	TGFBR2
6	Decreased viability	GR00221-A-1	11.16	AKT1 CDKN2A TGFBR2 EGFR KRAS PIK3CA
7	Decreased viability	GR00221-A-2	11.16	AKT1 KRAS PIK3CA
8	Decreased viability	GR00221-A-3	11.16	AKT1 ATM CDKN2A ERBB2 TGFBR2
9	Decreased viability	GR00221-A-4	11.16	AKT1 ATM CDKN2A ERBB2 TGFBR2 BRAF
10	Decreased viability	GR00249-S	11.16	AKT1 TGFBR2 BRAF MUC1
11	Decreased viability	GR00301-A	11.16	BRAF KRAS CDH1
12	Decreased viability	GR00381-A-1	11.16	BRAF KRAS
13	Decreased viability	GR00402-S-2	11.16	TGFBR2 PIK3CA CDH1
14	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	10.32	AKT1 BIRC5 CDKN2A RB1
15	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	10.32	AKT1 ATM BAX BIRC5 BRAF CDKN2A
16	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	10.32	ATM BAX TP53
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.93	KRAS
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.93	APC
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.93	BRAF
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-172	9.93	RB1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.93	RB1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-181	9.93	RB1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	9.93	APC
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	9.93	APC
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	9.93	RB1
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.93	AKT1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	9.93	KRAS
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.93	RB1
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.93	BRAF
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	9.93	RB1
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.93	AKT1 PIK3CA
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.93	KRAS
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	9.93	AKT1
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.93	AKT1
35	Increased cell viability after pRB stimulation	GR00230-A-1	9.62	AKT1 EGFR ERBB2 TGFBR2
36	Decreased viability after gemcitabine stimulation	GR00107-A-2	9.54	ATM CDKN2A TGFBR2
37	Decreased viability in pancreas lineage	GR00235-A	9.26	TGFBR2 TP53
38	Reduced mammosphere formation	GR00396-S	9.23	ATM BIRC5 BRAF CDH1 EGFR H19

MGI Mouse Phenotypes related to Adenocarcinoma:

⁴⁵ (show all 28)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.54	AKT1 APC ATM BAX BRAF CDH1
2	homeostasis/metabolism	MP:0005376	10.53	AKT1 APC ATM BAX BIRC5 BRAF
3	endocrine/exocrine gland	MP:0005379	10.5	AKT1 APC ATM BAX BIRC5 BRAF
4	nervous system	MP:0003631	10.49	AKT1 APC ATM BAX BRAF CDKN2A
5	growth/size/body region	MP:0005378	10.46	AKT1 APC ATM BAX BRAF CDH1
6	normal	MP:0002873	10.44	AKT1 APC BIRC5 BRAF CDH1 EGFR
7	embryo	MP:0005380	10.44	AKT1 APC ATM BIRC5 BRAF CDH1
8	muscle	MP:0005369	10.42	AKT1 APC BAX BRAF CDKN2A EGFR
9	cellular	MP:0005384	10.42	AKT1 APC ATM BAX BIRC5 BRAF
10	digestive/alimentary	MP:0005381	10.37	APC BRAF CDH1 CDKN2A EGFR EPCAM
11	cardiovascular system	MP:0005385	10.35	AKT1 APC ATM BRAF CDH1 CDKN2A
12	liver/biliary system	MP:0005370	10.34	AKT1 APC BRAF CDKN2A EGFR KRAS
13	immune system	MP:0005387	10.34	AKT1 APC ATM BAX BIRC5 BRAF
14	behavior/neurological	MP:0005386	10.3	AKT1 APC ATM BAX BRAF CDKN2A
15	no phenotypic analysis	MP:0003012	10.28	CDH1 CDKN2A EGFR EPCAM KRAS MUC1
16	renal/urinary system	MP:0005367	10.26	APC BAX BRAF EGFR KRAS RB1
17	pigmentation	MP:0001186	10.24	APC BRAF CDKN2A EGFR KRAS RB1
18	limbs/digits/tail	MP:0005371	10.24	APC BAX BRAF EGFR ERBB2 KRAS
19	adipose tissue	MP:0005375	10.24	AKT1 APC ATM BRAF EGFR PIK3CA
20	reproductive system	MP:0005389	10.21	AKT1 APC ATM BAX BRAF CDH1
21	craniofacial	MP:0005382	10.16	APC BRAF EGFR ERBB2 KRAS RB1
22	skeleton	MP:0005390	10.13	AKT1 APC BAX BRAF CDKN2A EGFR
23	hearing/vestibular/ear	MP:0005377	10.11	APC BAX BRAF EGFR KRAS RB1
24	respiratory system	MP:0005388	10.1	AKT1 BAX BRAF CDKN2A EGFR ERBB2
25	hematopoietic system	MP:0005397	10.03	AKT1 APC ATM BAX BIRC5 BRAF
26	vision/eye	MP:0005391	10	APC BAX BRAF CDKN2A EGFR KRAS
27	mortality/aging	MP:0010768	9.89	AKT1 APC ATM BAX BIRC5 BRAF
28	integument	MP:0010771	9.5	AKT1 APC ATM BRAF CDH1 CDKN2A

Sources

Drugs & Therapeutics for Adenocarcinoma

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron isomaltoside 1000

Approved, Investigational

Phase 4

1370654-58-2

Rabeprazole

Approved, Investigational

Phase 4

117976-89-3, 117976-90-6

5029

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Desflurane

Approved

Phase 4

57041-67-5

42113

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Prilocaine

Approved

Phase 4

721-50-6

4906

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Fesoterodine

Approved

Phase 4

286930-03-8, 286930-02-7

6918558

Osimertinib

Approved

Phase 4

1421373-65-0

71496458

Framycetin

Approved, Experimental, Vet_approved

Phase 4

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Gefitinib

Approved, Investigational

Phase 4

184475-35-2

123631

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Endostar protein

Phase 4

Adrenergic Agents

Phase 4

Anesthetics, Local

Phase 4

Hypnotics and Sedatives

Phase 4

Hepcidins

Phase 4

Cholinergic Agents

Phase 4

Anesthetics, Inhalation

Phase 4

Sodium Channel Blockers

Phase 4

Diuretics, Potassium Sparing

Phase 4

Muscarinic Antagonists

Phase 4

Cholinergic Antagonists

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, Dissociative

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Darbepoetin alfa

Approved, Investigational

Phase 2, Phase 3

209810-58-2

Medroxyprogesterone acetate

Approved, Investigational

Phase 3

520-85-4, 71-58-9

6279 10631

Celecoxib

Approved, Investigational

Phase 3

169590-42-5

2662

Ranitidine

Approved, Withdrawn

Phase 3

66357-59-3, 82530-72-1, 66357-35-5

3001055 5039

Chlorpheniramine

Approved

Phase 3

113-92-8, 132-22-9

2725

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Rosiglitazone

Approved, Investigational

Phase 3

122320-73-4, 155141-29-0

77999

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Midazolam

Approved, Illicit

Phase 3

59467-70-8

4192

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Estramustine

Approved, Investigational

Phase 3

2998-57-4

259331

Venlafaxine

Approved

Phase 3

99300-78-4, 93413-69-5

5656

Norepinephrine

Approved

Phase 3

51-41-2

439260

Cyproterone acetate

Approved, Investigational

Phase 3

427-51-0

9880

Interventional clinical trials:

(show top 50) (show all 3609)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation	Unknown status	NCT02283424	Phase 4	Icotinib;chemotherapy (Carboplatin and Docetaxel)
2	Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study	Unknown status	NCT02103257	Phase 4	Sequential Icotinib Plus Chemotherapy;Icotinib
3	Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative	Unknown status	NCT02804646	Phase 4	recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
4	Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma	Unknown status	NCT01665417	Phase 4	Experimental;Chemotherapy
5	Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma	Unknown status	NCT02399566	Phase 4	Erlotinib, Pemetrexed
6	An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma	Unknown status	NCT01927328	Phase 4	Iron isomaltoside 1000
7	The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer	Unknown status	NCT03401827	Phase 4	Chemotherapy (Gemcitabine + nab-paclitaxel)
8	Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study	Unknown status	NCT02194556	Phase 4	Sequential and maintenance icotinib;Maintenance icotinib
9	Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study	Completed	NCT00844675	Phase 4	rabeprazole;placebo
10	Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations	Completed	NCT01609543	Phase 4	erlotinib [Tarceva]
11	A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma	Completed	NCT00854477	Phase 4	capecitabine
12	An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
13	Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study	Completed	NCT02426034	Phase 4	ApatinibTablets
14	Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?	Completed	NCT02335151	Phase 4	Desflurane
15	Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study	Completed	NCT00578279	Phase 4	dehydrated alcohol
16	Clinical Outcomes of Endoscopic Resection for Treating Extremely Well Differentiated Intestinal-type Adenocarcinoma (WHYX Lesion)	Completed	NCT01451034	Phase 4
17	Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy	Completed	NCT02025361	Phase 4	intrarectal lidocaine gel;periprostatic nerve blockade
18	A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients	Completed	NCT02812992	Phase 4	Nab-paclitaxel;Gemcitabine
19	Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy	Completed	NCT03164590	Phase 4	Ketamine;dexmedetomidine;bupivacaine
20	A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy )	Completed	NCT01661166	Phase 4	Fesoterodine;Placebo oral tablet
21	Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer	Completed	NCT01579721	Phase 4
22	Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)	Completed	NCT02151149	Phase 4	nab-paclitaxel;Carboplatin
23	A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women	Completed	NCT01544478	Phase 4
24	PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma	Recruiting	NCT02366819	Phase 4	Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
25	PAXG Out in the Country	Recruiting	NCT04480268	Phase 4	PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
26	Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast	Recruiting	NCT05183828	Phase 4	Letrozole
27	Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study	Recruiting	NCT04401059	Phase 4	Elemene plus first or third generation EGFR-TKIs;First or third generation EGFR-TKIs
28	Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial	Active, not recruiting	NCT04281667	Phase 4	Oral Antibiotics;Placebo;Mechanical Bowel Preparation
29	Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.	Not yet recruiting	NCT02004782	Phase 4	Prednisolone;Placebo Oral Tablet
30	A Window-of-Opportunity Trial Using Neoadjuvant Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer	Not yet recruiting	NCT05634720	Phase 4	HA Chemotherapy
31	A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy	Terminated	NCT00536107	Phase 4	Gefitinib;Docetaxel
32	Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial.	Terminated	NCT02039115	Phase 4	prednisone;placebo
33	A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach	Terminated	NCT00871273	Phase 4	capecitabine
34	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy	Terminated	NCT01365143	Phase 4
35	A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma	Withdrawn	NCT03891979	Phase 4	Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
36	Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy	Withdrawn	NCT02570529	Phase 4	Albis®;Placebo
37	Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy	Withdrawn	NCT01401387	Phase 4
38	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	Unknown status	NCT00719303	Phase 3
39	Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	Unknown status	NCT02628665	Phase 3	photosensitizer(photofrin)
40	Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion	Unknown status	NCT02011997	Phase 3
41	A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	Unknown status	NCT00807768	Phase 3	Carboplatin;Paclitaxel
42	A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma	Unknown status	NCT02281708	Phase 3	vinorelbine plus cisplatin
43	Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma	Unknown status	NCT02518802	Phase 3	Gefitinib;Pemetrexed
44	Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation	Unknown status	NCT02929693	Phase 3	gefitinib;Yiqi-yangyin-jiedu decoction;placebo
45	Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.	Unknown status	NCT02072616	Phase 3
46	A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy.	Unknown status	NCT01941979	Phase 3	5-FU, Capecitabine, Oxaliplatin, Leucovorin.
47	A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy	Unknown status	NCT04342910	Phase 3	camrelizumab;Apatinib Mesylate;Paclitaxel;Irinotecan
48	Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial	Unknown status	NCT02780921	Phase 3
49	A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction	Unknown status	NCT01697917	Phase 3
50	Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma	Unknown status	NCT02289547	Phase 3	Capecitabine

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Thiotepa

Cochrane evidence based reviews: adenocarcinoma

Sources

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

#	Genetic test	Affiliating Genes
1	Adenocarcinoma ²⁸

Sources

Anatomical Context for Adenocarcinoma

Organs/tissues related to Adenocarcinoma:

MalaCards : Lung, Prostate, Pancreas, Lymph Node, Breast, Colon, T Cells

Sources

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 58400)

#	Title	Authors	PMID	Year
1	Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. ⁵³ ⁶²	Nagashio R...Okayasu I	19892429	2010
2	Role of CDK8 and beta-catenin in colorectal adenocarcinoma. ⁵³ ⁶²	Seo JO...Lim SC	20514474	2010
3	Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. ⁵³ ⁶²	Giaginis C...Theocharis SE	19949912	2010
4	Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. ⁵³ ⁶²	Minamiya Y...Ogawa J	19716197	2010
5	Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. ⁵³ ⁶²	Ooi A...Dobashi Y	20518902	2010
6	Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ⁵³ ⁶²	Yin A...Luo H	19415536	2010
7	The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. ⁵³ ⁶²	Han SL...Zeng QQ	20339853	2010
8	A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis. ⁵³ ⁶²	Hill M...Osinaga E	20197492	2010
9	HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. ⁵³ ⁶²	Malec V...Hanze J	20347035	2010
10	Identification of gastrointestinal contamination in endoscopic ultrasound-guided pancreatic fine needle aspiration. ⁵³ ⁶²	Toll AD...Bibbo M	20518405	2010
11	Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? ⁵³ ⁶²	Rensing KL...von der Thusen JH	20182859	2010
12	Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. ⁵³ ⁶²	Tarakji B...Sloan P	20038908	2010
13	True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. ⁵³ ⁶²	Hsu JD...Han CP	20407331	2010
14	Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. ⁵³ ⁶²	Murphy JP...Pinto DM	20213678	2010
15	The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. ⁵³ ⁶²	Mahalingam M...Hoang MP	20190734	2010
16	DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. ⁵³ ⁶²	Ikeda M...Sawai T	20372780	2010
17	Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. ⁵³ ⁶²	Kim JH...Choi C	20518411	2010
18	MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. ⁵³ ⁶²	Johnson MD...Xu H	20090516	2010
19	A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. ⁵³ ⁶²	Yang M...Nonaka D	20173733	2010
20	Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. ⁵³ ⁶²	Zhong WZ...Mok TS	20439191	2010
21	Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. ⁵³ ⁶²	Shintani M...Kamoshida S	20372850	2010
22	Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ⁵³ ⁶²	Han L...Feng J	19856421	2010
23	Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. ⁵³ ⁶²	Stewart CJ...Little L	20350213	2010
24	Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. ⁵³ ⁶²	Friederichs J...Sarbia M	19280218	2010
25	Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. ⁵³ ⁶²	Little L...Stewart CJ	20062011	2010
26	Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). ⁵³ ⁶²	Karamitopoulou E...Terracciano L	20350215	2010
27	Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. ⁵³ ⁶²	de Paiva Haddad LB...Jukemura J	20107918	2010
28	Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. ⁵³ ⁶²	Shafizadeh N...Kakar S	20040392	2010
29	Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. ⁵³ ⁶²	Fujiwara S...Yatabe Y	20004952	2010
30	Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. ⁵³ ⁶²	Hanna A...Michael CW	20146302	2010
31	Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. ⁵³ ⁶²	Plaza JA...Suster S	20377670	2010
32	Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. ⁵³ ⁶²	Eliasz S...Bocchetta M	20154720	2010
33	CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. ⁵³ ⁶²	Shin JH...Lee KY	19926591	2010
34	Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. ⁵³ ⁶²	Kristensen MH...Mejer J	20515563	2010
35	Integration of biomarkers including molecular targeted therapies in head and neck cancer. ⁵³ ⁶²	Williams MD	20237991	2010
36	Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? ⁵³ ⁶²	Glynn C...Ginsberg MS	20087229	2010
37	Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. ⁵³ ⁶²	Noguchi M	20108111	2010
38	Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma. ⁵³ ⁶²	Schaeffer DF...Owen DA	20091050	2010
39	Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. ⁵³ ⁶²	Zhou RM...Li Y	20074157	2010
40	SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. ⁵³ ⁶²	Miyoshi K...Tanaka M	20393008	2010
41	Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. ⁵³ ⁶²	Naguib A...Rodwell SA	20233436	2010
42	Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. ⁵³ ⁶²	Singh PB...Martin FL	19935673	2010
43	Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. ⁵³ ⁶²	Gomez-Fernandez C...Nadji M	19875957	2010
44	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. ⁵³ ⁶²	Takahashi T...Date H	20183914	2010
45	Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. ⁵³ ⁶²	Senchenko VN...Zabarovsky ER	20193080	2010
46	Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. ⁵³ ⁶²	Guldur ME...Bakir K	19609729	2010
47	Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. ⁵³ ⁶²	Cui Y...Han J	20158339	2010
48	Significance of mucin expression in pancreatobiliary neoplasms. ⁵³ ⁶²	Yonezawa S...Goto M	19787286	2010
49	The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers. ⁵³ ⁶²	Fritz JM...Malkinson AM	20101149	2010
50	Spindle proteins in resected pancreatic head adenocarcinomas: BubR1 is an independent prognostic factor in pancreatobiliary-type tumours. ⁵³ ⁶²	Gladhaug IP...Clausen OP	20459534	2010

Sources

Genes for Adenocarcinoma

Genes related to Adenocarcinoma (0 elite genes):

(show top 50) (show all 116)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	163.32	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8785513 9811352 11969291 (more) 19843670
2	HNF1A-AS1	HNF1A Antisense RNA 1	RNA Gene	155.4	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	24000294
3	TP53	Tumor Protein P53	Protein Coding	84.1	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions (show sections)	12823203 17982662 9379505 (more) 10674608 16375215 10748875 9446410 11812942 7730141 10684011 11479949 14583777 1551529 10445560 9221816 8912833 10382939 7738712 15167937 12469191 8697968 8606540 16575619 18752044 8209852 9203945 7960232 8076381 19339276 18759514 19234438 7642971 7614480 9221810 9155671 18322660 15725808 10463972 8527043 7665247 8033110 9627113 9209954 8066074 8194706 8685214 8751332 11940214 1344817 8014071 7573363 8623770 9607618 10674013 1656762 18019682 12771886 11353048 11051256 10677910 9024708 8829627 8291217 1279244 9888666 9807634 9661918 7582240 7794072 20076865 19471962 17592558 16552814 12907646 12792888 11706527 7547494 8205349 8097076 17354623 11751402 11570917 9793394 11866928 9646028 9460999 11244999 7723372 8311114 9690377 8781743 9816029 7728762 1615931 1680552 20232013 19174584 9368591 9241070
4	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	58.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions (show sections)	14511407 18075308 14724583 (more) 17360030 17904685 15771905 16235243 17321325 18636014 20087229 17354229 8814697 18932251 20101149 11431710 19797353 16533793 19270482 15815931 9196259 12438234 17093935 19064568 17591931 16878133 15638373 14742320 12696070 20305537 19824059 18374152 20009909 18669174 16598499 8389672 20034871 19028876 18090579 16452191 11291084 20108111 19238210 18223333 9612526 20018721 19270646 17468929 16060660 8288082 20183914 18059232 16863509 7475823 19813061 20023657 20108024 18235412 15597105 16585505 15604253 12606951
5	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	50.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions (show sections)	14724583 17360030 12438234 (more) 16598499 19440799 16376942 19369630 20305537 20233436 14688025 20496269 17293392 15729718 20103678 18059232 20237991 14507635 19159571 17351944 18636014
6	EGFR	Epidermal Growth Factor Receptor	Protein Coding	49.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	16449241 17321325 15211117 (more) 16052218 16189154 17409892 17721266 17561305 18997733 17580276 9706306 18829487 20040392 16503085 17354229 17211865 18208799 12377812 15604253 17493236 8098013 19724887 18559552 17409961 17238183 16795991 16623049 20439191 17549361 19609951 15950315 19064969 16731604 15832087 18932251 17904685 17264401 11496335 19270482 18976796 15120370 20518902 16702519 16552419 17784875 18054376 17093935 16533793 16857803 15329413 8920782 7802579 1325950 18776588 18636014 16598499 16027522 10686540 19622585 18304690 18453539 17699786 17761979 16549822 12884235 17473659 17186532 15769665 8856301 20087229 20180626 18543225 18391747 18027154 19357847 18585821 17618248 17493170 16353158 16532343 16815198 15746034 12441262 9698471 11879619 8625491 8181851 19596959 7912978 8020665 19706809 18355544 17493174 17505415 17409862 17487398 18154814 16140420 14607699
7	ATM	ATM Serine/Threonine Kinase	Protein Coding	48.83	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	47.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	15190415 15511476 17097832 (more) 19628076 16189154 7736397 10653878 15167937 9097992 19174584 16096400 20040392 1352687 17493384 16685109 16244586 1977376 10743084 8098013 9816029 7907434 16866851 11496335 11462947 1683776 18172343 11586103 9196297 9094152 7913137 8097369 9497105 9028739 15753357 2153076 1347282 20518902 17321325 8920782 9809997 9652760 7615357 1373318 1675057 20051815 15725808 15668283 15570074 7506116 15762277 11583287 11207822 7907608 19653727 15753987 12168842 10665910 8856301 16489645 16731604 16302076 15770690 11471321 8100854 2202801 1671001 8397058 10432004 7547494 7909319 1357006 17879632 15629613 18498074 9440619 9066744 17143264 7915830 1672262 8096075 7907421 9513719 11007435 11352401 12174921 17647268 17219742 16365600 15870067 15938112 15846117 15386424 15581047 14645692 15015590 14586404 12895227 14700481 15687589
9	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	45.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	18410530 15617840 16496173 (more) 18346352 18752124 12548164 16575619 15785933 15189501 9155671 12925390 17460447 19623034 17192788 8589035 9333024 19680686 11910361 16731604 12000709 10719365 12660006 12903406 17971901 12473584 9052747 9187111 11309302 17600882 17581420 16462152 15998377 15693199 15213599 15197775 9873831 9751261 14518304 7845688 17069677 9988232 18284933 15185075 9241072 9212218 9388844 19212685 17903034 9205067 7775254 15608367 19763614 20032395 18202755 15985168 12479060 11940214 10567907 17326708 16163549 16585505 9788631 8627645 11920733 11776846 9751761 9542513 9439668 19795445 19006382 19064568 16675157 8855976 7880531 20350213 19043591 18949413 17706134 16278815 14982856 12559346 9538137 10923439 19295407 18486890 15188135 15098254 12673679 12010891 15201980 14742312 14696398 12445746 20422865 19762530 19694828 14648656 14501820 10640976
10	SMAD4	SMAD Family Member 4	Protein Coding	44.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	11751510 11431719 17587453 (more) 17854080 15725808 12640108 10623651 11021814 10980115 12720172 18985820 14647445 15157044 8813122 14669329 11075857 12479060 17425384 11553622 11764071 10769633 19270646 18310076 19064568 9820739 14534532 15736060 15626919 12946833 12454109 11283934 9307274 18310088 14657708 9135016 16320109 11943721 10975709 10797313 10734643 10626800 19165547 17436386 9515793 15665291 15084978 10327057 11783110 11696422 17922593 15696124 14645346 19584151 9807701 11751474 11791187 11490843 11323508
11	EPCAM	Epithelial Cell Adhesion Molecule	Protein Coding	40.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Expressions (show sections)	19443410 15569986 15637741 (more) 15955212 8608965 12695858 14965442 1372428 19157637 8774141 1724706 19391212 15867145 16404366 10380012 10467371
12	BIRC5	Baculoviral IAP Repeat Containing 5	Protein Coding	39.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions Expressions (show sections)	18547619 19242064 11172305 (more) 16353082 16803539 15025964 11953819 16671090 15841045 17927889 15163019 16697865 15289739 16489645 12854136 16269299 12240548 16211215 18094614 19664395 19245589 17877643 16723855 18704463 12760292 16153440 15300213 19258429 15902487 15138717 12469143 15608672 12168867 19705503
13	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	39.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions Expressions (show sections)	10382939 15532837 12120204 (more) 17354623 9885381 15973073 11299743 11574518 9180925 10589765 14716828 9815673 17237283 10223575 11005569 10760438 14532726 15200918 16805752 9863489 17558861 16229013 15257106 8909234 18074738 11759059 11776517 11825479 8623925 17591046 10217615 9196162 9840618 15354213 11992551 11925595 11775833 10102608 9453486 16353209 15773546 12196918 19729672 14704000 16043260 17091766
14	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	39.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	19445727 16815198 19440799 (more) 19234438 18287584 18757405 19592505 15317667 16930767 18343945
15	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	38.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	10226558 9598801 11195465 (more) 15099960 12447993 11165397 12750289 18724388 10069452 9142180 9648930 10766860 17653092
16	RB1	RB Transcriptional Corepressor 1	Protein Coding	38.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	10382939 12197776 1329054 (more) 17487398 11497280 9988232 18593909 18383208 9531999 8302602 10605694 10440744 1552612 10071231 9017583 2294744 9542513 8910043 1751410 8371006
17	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	37.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	15946565 17210696 17895832
18	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	36.64	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	12163385 11559569 16235243 (more) 19606680 11315765 16991125 8616831 19259700 11304579 16278815 15287021 17167178 19576232 16407829 11338478 10626800 7958689 8950667 8552404 19197353 8943812 9433483 8019564 11677205 12165863 11943721 11448914 11107048 11062151 17418409 15492756 16336454 8081386 14518303 10590231
19	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	36.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Proteins (show sections)	8606540 10521973 19946103 (more) 17991319 17545600 10583575 9677444 17649808 12877727 18154934 12010364 9427605 9660721 12210083 12379756 16707592 11051251 8393050 8623771 11520144 15725805 11295067 8641670 19236510 19094709 18713982 15151204 12514429 10687132 7504258 15944787 1688543 9786354 11439371 12685546 15378790 17090193 19430419 18812166 18848661 18801090 17951204 17914488 17294451 17401217 17052316 7691840 1710419 1851775 19737144 17390044 17553459 16467101 15987679 12748245 19639217 17535681 19067858 18577115 16776849 15893750 15888109 12883236 11914624 18620991 16874487 16630141 15690331 12941828 12360467 11717535 11488073 10653872 9885912 9853552 9448015 9101416 7587872 7678777 11224609 10811121 10379682 10608618 8640896 7559911 19601472 17113977 15513966 12620150 11420467 11391628 8976874 8813954 7591241 7868083 11127148 10341360 7946402 1626180
20	CDH1	Cadherin 1	Protein Coding	36.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	11812942 16685438 9758359 (more) 11027430 11555590 7572899 15717748 12586803 11038427 12379748 9301546 15569371 18286686 19653727 12194995 12965318 10757409 15141378 17991319 11113858 15660698 16948518 16369055 16834907 15315156 10408414 20091050 16596173 11304579 15473932 18269642 17959228 16292101 16991125 12824891 16328348 16302076 14506634 9349237 9190996 8302730 7829238 12497652 8353041 9010457 9568505 19486012 9894451 1615930 20160041 19748854 18281780 17113977 15694044 15969753 15627055 8287621 10746678 8635021 17031402 17033799 16445817 15452164 14604226 14599963 16048394 12501215 12011119 10937343 15693887 15306932 12702045 12631658 12397640 11745459 10460003 10228494 11410776 9831199 8339265 1333788 19420730 1330938 19289031 15639718 12883236 12532469 11850584 10493977 9221804 11401320 18836777 16966438 15890089 15863126 14981918 11882822 10692217 11788563
21	ERBB4	Erb-B2 Receptor Tyrosine Kinase 4	Protein Coding	35.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries Pathways & Interactions (show sections)	16507107 17681096
22	CTNNB1	Catenin Beta 1	Protein Coding	35.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	20079187 12877730 9758359 (more) 11684954 12379748 15660698 12209953 12574842 11026105 11048797 16451736 16948518 14662019 16756720 16479254 15141378 10965019 15080308 11113858 14977843 10359135 16966438 11850584 11170292 17959228 18491352 12165863 11943721 9349237 16224588 15067731 12965318 15810077 19653727 12163385 19659475 11888085 14977820 15223963 15626916 15389251 10987283 18806829 18685490 17173289 15287021 15257551 15182426 14970870 12532469 15492756 16959701 12501215 12011119 11021815 18310088 17033799 16328013 15716238 15513360 15623628 12679314 11526497 10951334 19526105 17870207 15452164 12419858 11410776 9831199 19680686 18246043 18269642 17349568 15788657 15306932 12702045 12516970 11431710 8522310 20514474 19609729 12680208 12618757 11788563 11027430 15696124 15863126 15182428 12907644 11307154 10797268 18992165 19269007 15969753 11196159 16501564 17721186 17949785
23	CCND1	Cyclin D1	Protein Coding	34.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	20062011 9221810 10492044 (more) 9499189 15532837 20232013 12469159 16815198 14614307 12660006 14740230 10944553 10371338 12209953 12894495 9988232 20113529 18498074 15289739 9531999 9815783 9263512 19659475 18290692 16731604 14629750 11696421 11396138 16926627 15971196 14744730 10454255 10944540 17473212 16174239 9659580 8781742 19680686 18620991 14592662 14517835 10574260 9614448 11590324 17918209 17600882 14747065 11330579 11102889 10789011 10440744 10419705 20131501 15297940 14581353 12454109 9759649 9264360 9134998 11371120 10102608 9829756 11307154 15307143 15213599 12827612 10908361 10611246 10403547 9421073 15239347 12010891 11920733 17724476 15378768 11106243 16163549 12673692 11217450 11900573
24	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	34.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	10389722 12579092 15167937 (more) 19102938 10820344 16153457 15870864 15498380 16791450 15958546 12632503 16820877 19705030 14613646 15019676 9252720 20076865 17785951 15522212 15256117 11748468 9614439 12798704 16244586 15053037 16702519 19324448 15173661 9816315 9701011 18780893 15682485 18414651 12684660 12142733 16512994 12640714 17852856 17022010 16900513 16495697 11299793 12488200 12367793 11102890 18498074 15289739 9454658 9640218 16498312 14981918 11358838 17987799 9815567 9742525 10508818 18313673 17295646 16138121 16783964 15741767 15637689 15282704 15026340 17974973 11577444 11459932 12206019 10388459 19549464 18849317 16683386 15254661 12910515 12464871 12006453 11461089 11071270 16132575 12377649 17726369 16800965 16618579 16984727 16720317 15385105 14624783 14584665 12553038 12448000 11511786 10885428 7959603 20237991 19121088 15113042 12800229 12552943 11920479
25	BCL2	BCL2 Apoptosis Regulator	Protein Coding	34.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	9221816 10382939 12581249 (more) 8733771 18788571 9208811 9252682 14663927 20232013 10216484 11462947 15379952 16186958 10023698 8063611 12120204 8687162 12451034 8729986 9816161 10589765 8440743 12837981 9815673 8623925 11299743 10481119 8818693 8729985 8620509 20396555 18071066 10567896 15484295 14716828 11286130 7712429 11574518 9885381 9784987 9674186 9020491 15973073 9230856 14668542 11008204 10022131 9334622 10615232 16477877 17693084 15979837 15913739 15871560 15200918 11461089 10963109 10499481 10373674 8625322 15237588 12373289 10217615 9647593 9645443 9472684 9421084 9196162 8611422 9654593 9568186 9328178 8691340 20350213 8625232 20145299 16767924 12796161 11523052 11163106 10767713 10739702 10355530 10223575 11776517 9445135 16550596 15700269 8551385 7856728 18828269 17406756 17354623 17192048 16353209 16805752 15999157 15163019 11523051
26	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	34.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	11059772 12469191 12713622 (more) 14981968 12162677 11920515 9823297 15155531 18186150 11086200 9731479 15562904 14633942 11005569 10702199 9679948 15958546 15230726 18230181 16327494 12591965 10425287 17357536 14552327 18617777 18000398 16467169 10657949 15585388 11316217 10353732 17762961 16712734 9858942 18094611 15355919 16111807 15222037 19109152 18453539 15465199 15231484 16550596 15587390 11586094 16521222 16996907 16820089 12196918 10597402 15921850 18214062 16733863 15269153 14750244 11344234 9405496 14760075 12504222 10070951 17307036 16702519 11783060 10451445 12895344 8631005 19843025 19729335 18349295 17477358 17887937 17707579 17201164 16216410 16799479 16507392 15979837 15313405 15068324 14977856 14629099 12578839 11897504 10471521 9804170 19058955 18783518 17553653 17584489 17220580 16615003 16215757 16301573 16737669 15126378 12626523 11278747 10445576 9703885
27	SMAD3	SMAD Family Member 3	Protein Coding	34.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	9753318 15665291 10797313
28	SMAD2	SMAD Family Member 2	Protein Coding	33.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	15665291
29	RHOA	Ras Homolog Family Member A	Protein Coding	33.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	18495213 17273773 10373471
30	MLH1	MutL Homolog 1	Protein Coding	33.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	16984616 14657958 17316416 (more) 18192567 15676154 15354187 15064707 20336543 16336454 19694828 10408835 12636099 18161865 16048395 12823711 12808326 16784979 12627520 12384516 8674066 18059232 17276933 11532035 18942304 15069683 11306499 15492756 10766168 17203532 14645346 17167178
31	PTEN	Phosphatase And Tensin Homolog	Protein Coding	33.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	15025964 15172121 20079187 (more) 16220831 12632503 20102402 17927889 14689303 19010487 16489020 11586263 17638924 16810057 18788685 16803539 11431710 19242756 18268330 16803514 16919866 16912166 11349153 10955808 17713092 17452061 17348444 11553783 11259087 19234438 16764775 19125794 17488163 17020998 11109157 17418409 15129904 11395387 17349568 14522255 16515600 9887237 18383208 10514407 15025970 15583796 16772787
32	EGF	Epidermal Growth Factor	Protein Coding	33.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	12377812 8364119 10081495 (more) 8083436 10786684 7912978 12910515 17851837 7508115 8422702 18483390 9677101 2285597 10891365 7521866 11702192 2360455 1661653 1473218 18799374 16956694 16926627 11897504 10761690 10364198 9405304 14518215 8925996 16318410 12749846 7823598 1637682 1878344 17096356 12600830 8625491 8105439 1348589 17659651 11585739 10769641 7647987 16774944 10545752 8751604 7664907 1467326 1943115 2169292 20430737 18483264 15801978 11590324 10403829 9539953 8612509 8105122 1538276 1591048 2172119 12374462 7814196 1325950 9858340 1717146
33	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	32.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	15285310 12165863 19576232 (more) 19440799 20351699 17114585 19921196 16757341 8642043 11330579 8389672 1996309 18089810 18549475 1835900 18957720
34	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	32.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name (show sections)	17425390 12657964 11751498 (more) 16880135 17019794 19946103 17090193 16799633 17425384 15563666 15184872 17406026 11135323 19236510 17032197 16007204 15485908 11076872 8694545 14752841 10920259 16857800 17525742 17621592 17292332 15461591 18381409
35	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	32.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Summaries (show sections)
36	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	32.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	16259111 19740516 17636482 (more) 20173733 15832091 12698189 18577116 19438742
37	CYP2E1	Cytochrome P450 Family 2 Subfamily E Member 1	Protein Coding	32.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	7773503 9029171 9066584 (more) 17127240
38	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	32.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	12792888 18322660 17160237 (more) 10382939 12579284 10463972 9241070 1782077 7573363 20350215 12536310 8912833 8774478 9250158 17138864 16480585 15330218 10677910 9252682 11521990 9651176 9419978 9236898 15212949 12454109 11325852 10322679 16537179 11920733 11317955 11064455 9537203 1657384 18828269 12648589 1634140 19910837 18713757 11775833 15597105 11940214 11523051 9476908 16489095 17081704 17693084
39	MMP2	Matrix Metallopeptidase 2	Protein Coding	31.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18630474 15086833 15475447 (more) 9291433 16309203 10914717 10402168 11452866 10425288 7836420 9468552 8690299 11493755 14766248 12500407 20492173 12487935 9234385 8918435 10383907 11230703 11286133 11919158 19330734 8986779 8314319 19165547 17377415 11861388 11832162 10995877 8822116 12516105 10434927 10474026 9490275 11597382 15609323 12483270 11181677 10347682 18366007 12954092 12873995 15141378 8712742 9021726 16896992 12009237 16930329 17493236 7744701 9736043
40	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	31.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	8957065 17062664 18172343 (more) 19096300 8784474 7573364 17598453 15590419 8097369 8440743 17132227 15735036 9838902 10944610 16014115 7954397 16186806 14602140 7539865 9647593 16426920 15672865 11606073 9699182 11523050 18379349
41	MSH2	MutS Homolog 2	Protein Coding	31.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	11150379 18192567 15676154 (more) 12627520 18987546 15350299 17941949 18942304 11532035 16783774
42	MMP9	Matrix Metallopeptidase 9	Protein Coding	31.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	17493236 20332475 11882904 (more) 17278189 15086833 16687484 10434927 10914717 11493755 19596921 18630474 19141401 12500407 20492173 14750244 10672780 12954092 8918435 19885589 17222798 10474026 19526105 15246188 12487935 9234385 19549464 19529860 15000152 12516105 18706098 12483270 11861388 10995877 17378244 11181677 11452866 9918213 9021726 12009237 10402168 9792146
43	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	30.94	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)
44	STK11	Serine/Threonine Kinase 11	Protein Coding	30.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	12861065 12533684 12912948 (more) 16822578 9850045 11956081 19176640 17711506
45	TGFA	Transforming Growth Factor Alpha	Protein Coding	30.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	8606540 7508115 1989651 (more) 16926627 10732760 10081495 7852121 18054376 1337797 8625491 9677101 7814148 17562274 8642042 1591048 1696954 12645812 9127315 2249312 10951392 8612509 8020665 1538276 1794134 1648321 15025953 12454861 11371228 10545752 7573353 7664907 7539239 8097369 18986098 8199079 1348589 8334620 17851915 7528164 8467499 1661653 10545793 7814196 11727256 17647268
46	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	30.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	10782893 16507107 12618754 (more) 17631905 11102889 12896906 9127320
47	VEGFC	Vascular Endothelial Growth Factor C	Protein Coding	30.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	17354029 15958546 12168824 (more) 18061373 17316411 12604720 15173661 15086167 19582164 12518370 15637689 18310502 14584665 17022010 16474989 17629743
48	MST1R	Macrophage Stimulating 1 Receptor	Protein Coding	30.14	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)
49	CTHRC1	Collagen Triple Helix Repeat Containing 1	Protein Coding	30.1	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
50	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	30.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	15682485 16871430 17918209 (more) 12438264 17920763 15730617 16049285 15923602 17875759 18614255 15590419 15485908 16518408 15805288 18060032 17875724 16685378

Sources

Variations for Adenocarcinoma

ClinVar genetic disease variations for Adenocarcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.733G>A (p.Gly245Ser)	SNV	Likely Pathogenic	12365	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
2	ATM, C11orf65	NM_000051.4(ATM):c.6095G>A (p.Arg2032Lys)	SNV	Likely Pathogenic	181974	rs139770721	GRCh37: 11:108186638-108186638 GRCh38: 11:108315911-108315911

Copy number variations for Adenocarcinoma from CNVD:

⁶ (show all 49)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	25149	1	184907591	184916179	Amplification	PTGS2	Adenocarcinoma
2	33704	1	47467454	47552406	Amplification	STIL	Adenocarcinoma
3	66093	12	25249446	25295130	Amplification	KRAS	Adenocarcinoma
4	66576	12	3100000	5300000	Gain		Adenocarcinoma
5	66578	12	3100000	5300000	Gain		Adenocarcinoma
6	66580	12	3100000	5300000	Gain	TSPAN9	Adenocarcinoma
7	74649	13	109973413	110012072	Amplification	RAB20	Adenocarcinoma
8	87573	14	74815283	74818665	Amplification	FOS	Adenocarcinoma
9	93655	15	57100000	61500000	Loss	RORA	Adenocarcinoma
10	95696	15	79500000	83000000	Loss	DNM1P41	Adenocarcinoma
11	95698	15	79500000	83000000	Loss		Adenocarcinoma
12	95700	15	79500000	83000000	Loss		Adenocarcinoma
13	95702	15	79500000	83000000	Loss		Adenocarcinoma
14	95704	15	79500000	83000000	Loss		Adenocarcinoma
15	95706	15	79500000	83000000	Loss	LOC440300	Adenocarcinoma
16	95708	15	79500000	83000000	Loss		Adenocarcinoma
17	97921	16	14700000	16700000	Loss		Adenocarcinoma
18	107538	17	15900000	22100000	Loss		Adenocarcinoma
19	111139	17	35097918	35138441	Amplification	ERBB2	Adenocarcinoma
20	123836	18	89115825	89123587	Amplification	SPP1	Adenocarcinoma
21	135625	2	118600000	122100000	Gain		Adenocarcinoma
22	171545	3	169200000	172500000	Gain	MECOM	Adenocarcinoma
23	171548	3	169200000	172500000	Gain		Adenocarcinoma
24	171550	3	169200000	172500000	Gain	MECOM	Adenocarcinoma
25	172147	3	177300000	180600000	Gain	KCNMB3	Adenocarcinoma
26	172149	3	177300000	180600000	Gain	PIK3CA	Adenocarcinoma
27	172225	3	178866310	178952497	Gain	PIK3CA	Adenocarcinoma
28	172903	3	187500000	189400000	Gain	MASP1	Adenocarcinoma
29	173068	3	189400000	193800000	Gain	FGF12	Adenocarcinoma
30	173072	3	189400000	193800000	Gain	TP63	Adenocarcinoma
31	173431	3	193800000	199501827	Gain	RUBCN	Adenocarcinoma
32	173434	3	193800000	199501827	Gain		Adenocarcinoma
33	173436	3	193800000	199501827	Gain		Adenocarcinoma
34	173438	3	193800000	199501827	Gain		Adenocarcinoma
35	173440	3	193800000	199501827	Gain		Adenocarcinoma
36	173442	3	193800000	199501827	Gain	OPA1	Adenocarcinoma
37	206066	6	135544145	135582003	Amplification	MYB	Adenocarcinoma
38	218057	7	107200000	137300000	Amplification		Adenocarcinoma
39	218695	7	116312458	116438439	Copy number	MET	Adenocarcinoma
40	225387	7	45400000	54000000	Copy number	EGFR	Adenocarcinoma
41	226106	7	55054218	55242525	Amplification	EGFR	Adenocarcinoma
42	230093	7	97900000	104400000	Gain	TRRAP	Adenocarcinoma
43	230096	7	97900000	104400000	Gain	ZKSCAN1	Adenocarcinoma
44	230097	7	97900000	104400000	Gain	ZNF3	Adenocarcinoma
45	230098	7	97900000	104400000	Gain	ZSCAN21	Adenocarcinoma
46	233908	8	128816946	128822855	Amplification	MYC	Adenocarcinoma
47	239383	8	38973661	39081936	Amplification	ADAM9	Adenocarcinoma
48	240761	8	55041668	55097561	Translate	TCEA1	Adenocarcinoma
49	241225	8	59800000	146274826	Copy number		Adenocarcinoma

Sources

Expression for Adenocarcinoma

Search GEO for disease gene expression data for Adenocarcinoma.

Sources

Pathways for Adenocarcinoma

Pathways related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 145)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.17	TP53 SMAD4 RB1 KRAS ERBB2 EGFR
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.87	TP53 TGFBR2 SMAD4 RB1 PIK3CA MUC1
3	Signal Transduction ⁶⁶	13.86	TP53 TGFBR2 SMAD4 PIK3CA KRAS ERBB2
4	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.86	AKT1 APC ATM BAX BRAF CDH1
5	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.8	AKT1 BIRC5 BRAF CDKN2A EGFR ERBB2
6	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.72	TP53 SMAD4 KRAS ERBB2 EGFR BRAF
7	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.64	AKT1 BAX BRAF CDH1 EGFR ERBB2
8	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.58	AKT1 APC ATM BAX BRAF CDKN2A
9	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.5	AKT1 APC BRAF EGFR ERBB2 KRAS
10	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.42	AKT1 BAX CDH1 EGFR ERBB2 KRAS
11	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.38	KRAS ERBB2 EGFR CDH1 BRAF APC
12	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	13.06	TP53 CDKN2A BIRC5 BAX ATM AKT1
13	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	13.04	TP53 PIK3CA EGFR CDKN2A BIRC5 BAX
14	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	13	TGFBR2 PIK3CA KRAS ERBB2 EGFR BRAF
15	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.97	TP53 TGFBR2 SMAD4 PIK3CA KRAS BRAF
16	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.96	AKT1 BAX BRAF EGFR ERBB2 KRAS
17	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.95	PIK3CA KRAS BRAF BIRC5 AKT1
18	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.94	PIK3CA KRAS EGFR BRAF AKT1
19	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.93	AKT1 APC BRAF KRAS PIK3CA
20	Programmed Cell Death ⁶⁶ Show member pathways Apoptosis ⁶⁶	12.81	TP53 CDKN2A CDH1 BAX APC AKT1
21	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.81	TP53 RB1 KRAS EGFR BRAF AKT1
22	Malignant pleural mesothelioma ⁷⁴	12.81	AKT1 APC ATM BAX CDH1 CDKN2A
23	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.78	TP53 RB1 PIK3CA KRAS EGFR ATM
24	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.77	AKT1 BRAF CDKN2A EGFR KRAS
25	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.75	TP53 TGFBR2 SMAD4 RB1 PIK3CA KRAS
26	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.72	AKT1 BAX BIRC5 EGFR ERBB2 KRAS
27	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.6	TGFBR2 SMAD4 RB1 APC AKT1
28	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.6	TP53 PIK3CA ERBB2 CDH1 BRAF BAX
29	WNT Signaling ⁶⁴	12.57	TP53 RB1 CDH1 BIRC5 APC AKT1
30	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.57	TP53 PIK3CA MUC1 KRAS ERBB2 EGFR
31	MAPK signaling pathway ⁷⁴	12.55	AKT1 BRAF EGFR KRAS TGFBR2 TP53
32	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.54	AKT1 ATM BAX EGFR ERBB2 KRAS
33	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.53	TP53 SMAD4 RB1 PIK3CA KRAS ERBB2
34	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.51	TGFBR2 SMAD4 PIK3CA MUC1
35	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.51	PIK3CA KRAS ERBB2 EGFR CDH1 BRAF
36	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.5	PIK3CA KRAS EGFR AKT1
37	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.49	AKT1 BRAF KRAS PIK3CA
38	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.47	TGFBR2 SMAD4 RB1 CDKN2A
39	Death Receptor Signaling ⁶⁷ Show member pathways Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathway ⁶⁵ SARS-CoV-1-mediated effects on programmed cell death ⁶⁶ TNF Signaling ⁶⁷	12.46	TP53 BIRC5 BAX AKT1
40	Focal adhesion ⁷⁴	12.43	PIK3CA ERBB2 EGFR BRAF AKT1
41	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.42	PIK3CA ERBB2 EGFR AKT1
42	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.4	ATM CDKN2A RB1 SMAD4 TP53
43	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.37	PIK3CA EGFR BRAF AKT1
44	Integrin-mediated cell adhesion ⁷⁴ Show member pathways HGF Pathway ⁶⁴	12.36	RB1 KRAS BRAF AKT1
45	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.36	TP53 PIK3CA BAX AKT1
46	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.36	TP53 RB1 BAX ATM AKT1
47	Ras signaling ⁷⁴	12.35	PIK3CA KRAS EGFR AKT1
48	Intrinsic Pathway for Apoptosis ⁶⁶ Show member pathways Activation of BAD and translocation to mitochondria ⁶⁶ Activation of BH3-only proteins ⁶⁶ Activation of BIM and translocation to mitochondria ⁶⁶ Activation of BMF and translocation to mitochondria ⁶⁶ Activation of NOXA and translocation to mitochondria ⁶⁶ Activation of PUMA and translocation to mitochondria ⁶⁶ Activation, myristolyation of BID and translocation to mitochondria ⁶⁶ Apoptotic factor-mediated response ⁶⁶ BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members ⁶⁶ Cytochrome c-mediated apoptotic response ⁶⁶ Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function ⁶⁶ Release of apoptotic factors from the mitochondria ⁶⁶ SMAC, XIAP-regulated apoptotic response ⁶⁶	12.35	TP53 CDKN2A BAX AKT1
49	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.35	PIK3CA KRAS ERBB2 EGFR
50	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.33	TP53 TGFBR2 SMAD4 PIK3CA KRAS CDH1

Sources

GO Terms for Adenocarcinoma

Biological processes related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 31)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.42	AKT1 BIRC5 EGFR EPCAM ERBB2 KRAS
2	protein phosphorylation	GO:0006468	10.41	AKT1 ATM BIRC5 BRAF EGFR ERBB2
3	positive regulation of gene expression	GO:0010628	10.35	TP53 KRAS ERBB2 CDKN2A BRAF ATM
4	regulation of apoptotic process	GO:0042981	10.27	TP53 BIRC5 BAX ATM AKT1
5	negative regulation of cell growth	GO:0030308	10.22	CDKN2A RB1 SMAD4 TP53
6	apoptotic process	GO:0006915	10.22	TP53 TGFBR2 RB1 CDKN2A BIRC5 BAX
7	positive regulation of peptidyl-serine phosphorylation	GO:0033138	10.19	PIK3CA EGFR BRAF AKT1
8	Ras protein signal transduction	GO:0007265	10.19	TP53 RB1 KRAS CDKN2A
9	negative regulation of cell population proliferation	GO:0008285	10.17	TP53 TGFBR2 SMAD4 RB1 CDKN2A BAX
10	phosphatidylinositol 3-kinase signaling	GO:0014065	10.12	PIK3CA ERBB2 AKT1
11	cellular response to epidermal growth factor stimulus	GO:0071364	10.12	ERBB2 EGFR AKT1
12	ovarian follicle development	GO:0001541	10.11	SMAD4 BAX ATM
13	negative regulation of neuron apoptotic process	GO:0043524	10.11	BAX BIRC5 BRAF KRAS PIK3CA
14	positive regulation of protein phosphorylation	GO:0001934	10.11	AKT1 BIRC5 BRAF EGFR ERBB2 KRAS
15	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	10.03	TP53 MUC1 ATM
16	gastrulation	GO:0007369	10.01	TP53 TGFBR2 SMAD4
17	cellular response to growth factor stimulus	GO:0071363	10.01	AKT1 EGFR ERBB2 TGFBR2
18	epidermal growth factor receptor signaling pathway	GO:0007173	10.01	PIK3CA EGFR BRAF AKT1
19	replicative senescence	GO:0090399	10	TP53 CDKN2A ATM
20	striated muscle cell differentiation	GO:0051146	9.99	RB1 KRAS AKT1
21	glial cell proliferation	GO:0014009	9.97	TP53 RB1 KRAS
22	regulation of cell cycle	GO:0051726	9.97	APC ATM BAX BIRC5 CDKN2A RB1
23	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.95	TP53 MUC1
24	apoptotic mitochondrial changes	GO:0008637	9.95	CDKN2A BAX AKT1
25	regulation of cell population proliferation	GO:0042127	9.92	TP53 TGFBR2 SMAD4 ERBB2 EGFR BRAF
26	response to UV-A	GO:0070141	9.91	EGFR AKT1
27	neuron apoptotic process	GO:0051402	9.91	TP53 RB1 KRAS BAX ATM
28	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.81	ERBB2 CDKN2A
29	regulation of mitochondrial membrane permeability involved in apoptotic process	GO:1902108	9.8	TP53 BAX
30	phosphorylation	GO:0016310	9.65	TGFBR2 PIK3CA ERBB2 EGFR CDKN2A BRAF
31	cell population proliferation	GO:0008283	9.28	TP53 SMAD4 RB1 KRAS EGFR BAX

Molecular functions related to Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.02	AKT1 ATM BAX BIRC5 BRAF CDH1
2	nucleotide binding	GO:0000166	9.92	TGFBR2 PIK3CA KRAS ERBB2 EGFR BRAF
3	protein kinase activity	GO:0004672	9.76	TGFBR2 ERBB2 EGFR BRAF ATM AKT1
4	disordered domain specific binding	GO:0097718	9.65	TP53 RB1 CDKN2A
5	kinase activity	GO:0016301	9.32	TGFBR2 PIK3CA ERBB2 EGFR CDKN2A BRAF